Earnings summaries and quarterly performance for CytomX Therapeutics.
Executive leadership at CytomX Therapeutics.
Board of directors at CytomX Therapeutics.
Research analysts who have asked questions during CytomX Therapeutics earnings calls.
Mitchell Kapoor
H.C. Wainwright & Co.
5 questions for CTMX
Also covers: HALO, INM, IONS +7 more
Peter Lawson
Barclays PLC
4 questions for CTMX
Also covers: ADAP, ARVN, BPMC +15 more
Anupam Rama
JPMorgan Chase & Co.
3 questions for CTMX
Also covers: APLS, BBIO, BOLD +16 more
Edward Tenthoff
Piper Sandler Companies
2 questions for CTMX
Also covers: ARVN, ARWR, CAPR +14 more
Matthew Biegler
Oppenheimer & Co. Inc.
2 questions for CTMX
Also covers: ALLO, ARVN, FULC +2 more
Nabeel Nissar
Jefferies
2 questions for CTMX
Dan (on for Mitchell Kapoor)
H.C. Wainright
1 question for CTMX
Etzer Darout
BMO Capital Markets
1 question for CTMX
Also covers: ARVN, EXEL, GMAB +5 more
Jeff
B. Riley
1 question for CTMX
Also covers: NIO
Jiale Song
Jefferies Financial Group Inc.
1 question for CTMX
Also covers: ACRS, CRVS, CVAC +12 more
Joe Catanzaro
Piper Sandler
1 question for CTMX
Also covers: AADI, CNTB, IMAB +1 more
Joseph Catanzaro
Wolfe Research, LLC
1 question for CTMX
Also covers: AADI, CPRX, CRDF +7 more
Liang Cheng
Jefferies
1 question for CTMX
Also covers: AADI, INO, VXRT
Robert Driscoll
Wedbush Securities
1 question for CTMX
Also covers: CMPX
Recent press releases and 8-K filings for CTMX.
CytomX Highlights Positive Clinical Data for CX-2051 and CX-801, Reports Strong Financial Position
CTMX
Guidance Update
New Projects/Investments
- CytomX reported encouraging Phase 1 data for CX-2051 in metastatic colorectal cancer, demonstrating a 28% confirmed response rate and 5.8 months progression-free survival in late-stage patients. The company aims for a registrational path as monotherapy, with an update expected in Q1 2026 and a bevacizumab combination study initiating in Q1 2026.
- Early Phase 1 data for CX-801 in melanoma showed the drug's mechanism is working as designed, activating interferon-responsive genes and recruiting T cells. A combination study with Keytruda is ongoing, with data anticipated in late 2026.
- The company is in a robust financial position, with $144 million in cash at the end of Q3 (subsequently $150-$158 million with ATM), providing funding into Q2 2027. This enables continued clinical development for both CX-2051 and CX-801.
- The positive clinical data for CX-2051 has validated CytomX's Probody platform, and the company remains open to additional platform partnerships.
3 days ago
CytomX Discusses Clinical Pipeline and Financial Outlook at Piper Sandler Conference
CTMX
Product Launch
New Projects/Investments
Guidance Update
- CytomX reported encouraging Phase 1 data for its masked anti-EpCAM ADC, CX-2051, in metastatic colorectal cancer, showing a 28% confirmed response rate and 5.8 months progression-free survival in late-line patients. The company plans to provide an update in Q1 next year and aims for a registrational path as monotherapy, with a combination study with bevacizumab initiating in Q1 next year.
- Early Phase 1 data for CX-801, a masked interferon alpha-2b, in melanoma demonstrated compelling biomarker data, including activation of interferon responsive genes and recruitment of CD8 positive T cells into the tumor microenvironment. A combination study with Keytruda began earlier this year, with data expected in late 2026.
- CytomX ended Q3 with $144 million in cash, providing funding into Q2 2027, which supports ongoing clinical studies for CX-2051 and CX-801.
- The company is open for additional platform partnerships on the discovery side, leveraging its Probody platform.
3 days ago
CytomX Provides Updates on Clinical Pipeline and Financial Outlook
CTMX
New Projects/Investments
Guidance Update
- CytomX reported encouraging Phase 1 data for CX-2051 (EpCAM ADC) in metastatic colorectal cancer in May 2025, demonstrating a 28% confirmed response rate and 5.8 months progression-free survival in late-stage patients. An update on the expanded Phase 1 study is anticipated in Q1 2026.
- Early Phase 1 data for CX-801 (masked interferon alpha-2b) in melanoma, presented at SITC, showed activation of interferon responsive genes and recruitment of CD8 positive T cells into the tumor microenvironment. Combination therapy with Keytruda began in 2025, with data expected in late 2026.
- The company concluded Q3 2025 with $144 million in cash, which is expected to fund operations into Q2 2027.
3 days ago
CytomX Provides Update on CX2051 Colorectal Cancer Data and CX-801 Program
CTMX
New Projects/Investments
Guidance Update
- CytomX (CTMX) is developing CX2051, a masked antibody-drug conjugate (ADC) targeting EpCAM for colorectal cancer (CRC).
- Initial Phase 1 dose escalation data for CX2051 in late-stage CRC patients (median of four prior therapies) showed a 28% confirmed response rate in 18 efficacy-evaluable patients, 94% disease control, and 5.8 months of progression-free survival (PFS).
- The Phase 1 study for CX2051 is expanding to 100 patients, with the next data update anticipated in Q1 2026.
- CytomX is also developing CX-801, a masked interferon alpha-2b, with preliminary data showing activation of interferon signaling in tumors. A combination study of CX-801 with Keytruda is underway, with data expected in late-stage melanoma in 2026.
5 days ago
CytomX Updates on CX-2051 Colorectal Cancer Data and CX-801 Development
CTMX
New Projects/Investments
- CytomX's lead asset, CX-2051, an EpCAM-targeting antibody-drug conjugate (ADC), demonstrated a 28% confirmed response rate and 5.8 months progression-free survival in initial Phase 1 data from 18 efficacy evaluable late-stage colorectal cancer patients.
- The Phase 1 study for CX-2051 is expanding enrollment to 100 patients, with the next data update planned for Q1 2026.
- CytomX intends to initiate a Bev combination Phase Ib study for CX-2051 in Q1 2026 and explore non-colorectal cancer indications in 2026.
- The company is also developing CX-801, a masked interferon alpha-2b, with combination data with Keytruda in late-stage melanoma expected by the end of 2026.
5 days ago
CytomX Therapeutics Highlights Promising CX-2051 Phase 1 Data and Q1 2026 Data Disclosure
CTMX
New Projects/Investments
Guidance Update
- CytomX Therapeutics reported promising Phase 1 data for its EpCAM ADC program, CX-2051, in May 2025, demonstrating a 28% confirmed overall response rate and 5.8 months preliminary progression-free survival in late-stage colorectal cancer patients, significantly exceeding the 1-2% response rates and ~3 months PFS of current standard of care.
- The company plans to disclose additional data for CX-2051 in Q1 2026, with enrollment expanded to approximately 100 patients to confirm efficacy, further assess safety, and determine optimal dosing for future studies.
- CytomX is actively addressing a 21% Grade 3 diarrhea signal observed with CX-2051 by implementing prophylactic loperamide, with updates on mitigation strategies expected in the Q1 2026 data release.
- The company reported a strong financial position with cash of just under $150 million, which is expected to fund operations into Q2 2027.
Nov 20, 2025, 1:00 PM
CytomX Therapeutics Provides Update on ProBody Platform and CX-2051 Program
CTMX
New Projects/Investments
Guidance Update
- CytomX Therapeutics (CTMX) reported promising Phase 1 data for its CX-2051 EpCAM ADC program in May 2025, showing a 28% confirmed overall response rate and 5.8 months preliminary progression-free survival in late-line colorectal cancer patients, significantly exceeding the 1-2% response rates and 3-3.5 months PFS of current standard of care.
- The company has increased enrollment for the CX-2051 study to an anticipated 100 patients by the Q1 2026 data disclosure, with plans to discuss a potentially registrational trial design with the FDA in 2026.
- While CX-2051 demonstrated a favorable safety profile, a 21% rate of grade three diarrhea was observed, which the company is addressing with prophylactic loperamide, with further updates expected in Q1 2026.
- CytomX reported a cash position of just under $150 million, providing funding into Q2 2027.
Nov 20, 2025, 1:00 PM
CytomX Therapeutics Provides Update on CX-2051 Clinical Program and Financial Position
CTMX
Product Launch
New Projects/Investments
- CytomX Therapeutics, utilizing its ProBody Therapeutic Platform, reported promising Phase 1 data in May 2025 for CX-2051, a masked EpCAM antibody-drug conjugate (ADC) targeting late-stage colorectal cancer (CRC).
- The initial data for CX-2051 demonstrated a confirmed overall response rate of 28% and a preliminary progression-free survival of 5.8 months in a patient population where the current standard of care typically yields 1-2% response rates and approximately 3 months PFS.
- Enrollment for CX-2051 has been expanded to approximately 100 patients, with the next data disclosure anticipated in Q1 2026. The company aims to confirm efficacy, further understand the safety profile, and select a dose for potential registrational studies in 2026.
- CytomX reported a cash balance of just under $150 million, providing a cash runway into Q2 2027, and maintains ongoing partnerships with Regeneron and Astellas.
Nov 20, 2025, 1:00 PM
CytomX Therapeutics Reports Q3 2025 Financial Results and Clinical Program Updates
CTMX
Earnings
Guidance Update
New Projects/Investments
- CytomX Therapeutics ended Q3 2025 with $143.6 million in cash, cash equivalents, and investments, projecting a cash runway to at least Q2 2027. Total revenue for the quarter was $6 million, a decrease from $33.4 million in Q3 2024, attributed to the completion of a collaboration's performance obligations.
- The company's lead drug candidate, CX-2051 for colorectal cancer, is on track for a data update in Q1 2026, with total Phase I study enrollment expected to reach approximately 100 patients. A Phase IB study combining CX-2051 with bevacizumab is anticipated to begin in Q1 2026.
- Progress continues with CX-801 in advanced melanoma, with initial biomarker data presented at SITC demonstrating robust interferon signaling. Initial data for the CX-801-Keytruda combination is expected by the end of 2026. The company also highlighted a new preclinical program, CX-908, a masked T cell engager.
Nov 6, 2025, 10:00 PM
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Business Update
CTMX
Earnings
Guidance Update
New Projects/Investments
- CytomX Therapeutics reported a net loss of $14.2 million (or $(0.09) per share) for Q3 2025, with total revenue of $6.0 million, down from $33.4 million in Q3 2024.
- The company ended Q3 2025 with $143.6 million in cash, cash equivalents, and investments, projecting a cash runway into the second quarter of 2027.
- Key pipeline updates include a CX-2051 Phase 1 data update on track for Q1 2026 and the planned start of a Phase 1b combination study in CRC in Q1 2026. Additionally, positive CX-801 Phase 1 monotherapy biomarker data was presented at SITC 2025, with initial clinical data for the combination study with KEYTRUDA® anticipated in 2026.
Nov 6, 2025, 9:12 PM
Quarterly earnings call transcripts for CytomX Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more